Beta-Thalassaemia — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Haemoglobinopathies and health disparities: findings of a large-scale sample survey among indigenous populations in Odisha, India.
Bhattacharya Haimanti et al. — BMJ open (27 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41895803/
- 2.
Evaluation of Liver Iron Accumulation With Liver Elastography and Apparent Diffusion Coefficient in Children With Thalassaemia Major.
Kaya Murat et al. — Journal of medical imaging and radiation oncology (13 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41826250/
- 3.
Investigating beta-thalassaemia in micro-CT scans of deciduous teeth.
Garnett Elizabeth M et al. — International journal of paleopathology (2 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41775229/
- 4.
Assessment of services for diagnosis, management and prevention of thalassaemia in India: The way forward.
Radhakrishnan Nita et al. — Vox sanguinis (1 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41320182/
- 5.
Altered cerebral morphometry and individual-based morphological brain network in children with beta-thalassaemia major
Yaowen Li et al. — Neuroscience (29 January 2026)
https://doi.org/10.1016/j.neuroscience.2026.01.036
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Recruiting — Phase 3 — Celgene
https://clinicaltrials.gov/study/NCT04064060
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Beta-Thalassaemia
Beta-thalassaemia is an inherited blood disorder caused by mutations in the HBB gene that reduce or eliminate production of the beta-globin protein, leading to anaemia of varying severity. The severe form (thalassaemia major) requires lifelong blood transfusions. Gene therapies and gene editing approaches are transforming treatment options.
Most Recent Research
OBJECTIVES: To estimate the prevalence of sickle cell trait, sickle cell disease, beta-thalassaemia minor and beta-thalassaemia major among Odisha's indigenous populations and to examine associated haematological profiles and survival outcomes based on socioeconomic factors. DESIGN: A population-based cross-sectional study. SETTING: Fourteen tribal-dominated districts of Odisha, eastern India PARTICIPANTS: A total of 8774 tribal individuals aged 11 months to 99 years, selected using multistage cluster sampling from 9711 households. PRIMARY AND SECONDARY OUTCOME: Primary outcomes were the prevalence of sickle cell trait, sickle cell disease, beta-thalassaemia minor and beta-thalassaemia major. Secondary outcomes included haemoglobin levels, serum iron, unsaturated iron-binding capacity, awareness regarding the diseases, nutritional status and estimated survival by sex and wealth quintile. RESULTS: The prevalence of sickle cell trait was 5.20%, sickle cell disease 0.40%, beta-thalassaemia minor 4.18%, and beta-thalassaemia major 0.44%. Females had slightly higher traits and minor prevalence, while the disease was more common in males; however, these differences are not statistically significant. Median serum iron levels were higher among individuals with β-thalassaemia major, while individuals with sickle cell disease exhibited consistently lower haemoglobin levels. Awareness was critically low (15.28%). Nutritional status and survival differed by condition, sex and wealth. Median survival was lowest for sickle cell disease and among the poorest, highlighting the need for targeted screening and education. CONCLUSION: This study highlights the substantial burden of haemoglobinopathies and significant health disparities among the Indigenous populations of Odisha. Expanding screening initiatives, enhancing health education and integrating haemoglobinopathy management into primary healthcare services are crucial for reducing disease burden and improving survival outcomes.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.